NO20024971L - Forbedringer av formuleringer for anvendelse i inhaleringsinnretninger - Google Patents

Forbedringer av formuleringer for anvendelse i inhaleringsinnretninger

Info

Publication number
NO20024971L
NO20024971L NO20024971A NO20024971A NO20024971L NO 20024971 L NO20024971 L NO 20024971L NO 20024971 A NO20024971 A NO 20024971A NO 20024971 A NO20024971 A NO 20024971A NO 20024971 L NO20024971 L NO 20024971L
Authority
NO
Norway
Prior art keywords
formulation
active substance
particles
inhalation device
inhalers
Prior art date
Application number
NO20024971A
Other languages
English (en)
Norwegian (no)
Other versions
NO20024971D0 (no
Inventor
John Nicholas Staniforth
David Alexander Vodden Morton
Rajbir Gill
Gaetano Brambilla
Rossella Musa
Lorenzo Ferrarini
Original Assignee
Vectura Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26071084&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20024971(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB0009469.8A external-priority patent/GB0009469D0/en
Application filed by Vectura Ltd filed Critical Vectura Ltd
Publication of NO20024971D0 publication Critical patent/NO20024971D0/no
Publication of NO20024971L publication Critical patent/NO20024971L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20024971A 2000-04-17 2002-10-16 Forbedringer av formuleringer for anvendelse i inhaleringsinnretninger NO20024971L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0009469.8A GB0009469D0 (en) 2000-04-17 2000-04-17 Improvements in or relating to formalities for use in inhaler devices
EP00113608 2000-06-27
PCT/GB2001/001732 WO2001078694A2 (en) 2000-04-17 2001-04-17 Formulations for use in inhaler devices

Publications (2)

Publication Number Publication Date
NO20024971D0 NO20024971D0 (no) 2002-10-16
NO20024971L true NO20024971L (no) 2002-12-17

Family

ID=26071084

Family Applications (4)

Application Number Title Priority Date Filing Date
NO20024971A NO20024971L (no) 2000-04-17 2002-10-16 Forbedringer av formuleringer for anvendelse i inhaleringsinnretninger
NO20024973A NO342999B1 (no) 2000-04-17 2002-10-16 Pulver for bruk i en tørrpulverinhalator, samt fremgangsmåte for fremstilling derav
NO20024980A NO332025B1 (no) 2000-04-17 2002-10-16 Farmasoytiske formuleringer for torrpulverinhalatorer i form av harde pelleter
NO20110885A NO336687B1 (no) 2000-04-17 2011-06-20 Farmasøytiske formuleringer for tørt pulverinhalatorer i form av harde pelleter

Family Applications After (3)

Application Number Title Priority Date Filing Date
NO20024973A NO342999B1 (no) 2000-04-17 2002-10-16 Pulver for bruk i en tørrpulverinhalator, samt fremgangsmåte for fremstilling derav
NO20024980A NO332025B1 (no) 2000-04-17 2002-10-16 Farmasoytiske formuleringer for torrpulverinhalatorer i form av harde pelleter
NO20110885A NO336687B1 (no) 2000-04-17 2011-06-20 Farmasøytiske formuleringer for tørt pulverinhalatorer i form av harde pelleter

Country Status (32)

Country Link
US (4) US8182791B2 (cs)
EP (6) EP1719505B1 (cs)
JP (2) JP2003530425A (cs)
KR (1) KR20030069047A (cs)
CN (1) CN1424909A (cs)
AT (5) ATE348603T1 (cs)
AU (3) AU2001258343A1 (cs)
BR (3) BR0110141A (cs)
CA (3) CA2406201C (cs)
CY (1) CY1107315T1 (cs)
CZ (1) CZ301904B6 (cs)
DE (3) DE60123031T2 (cs)
DK (3) DK1719505T3 (cs)
DZ (1) DZ3315A1 (cs)
EE (1) EE05257B1 (cs)
ES (3) ES2292576T3 (cs)
GB (2) GB2363987A (cs)
HU (4) HU229270B1 (cs)
IL (1) IL152306A0 (cs)
MA (1) MA26892A1 (cs)
MX (3) MXPA02010212A (cs)
MY (1) MY129384A (cs)
NO (4) NO20024971L (cs)
NZ (1) NZ521887A (cs)
PE (1) PE20011227A1 (cs)
PL (3) PL204213B1 (cs)
PT (3) PT1719505E (cs)
SA (1) SA01220062B1 (cs)
SI (2) SI1719505T1 (cs)
SK (1) SK284248B6 (cs)
TN (1) TNSN01060A1 (cs)
WO (3) WO2001078694A2 (cs)

Families Citing this family (170)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501841D0 (en) * 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
GB9515182D0 (en) * 1995-07-24 1995-09-20 Co Ordinated Drug Dev Improvements in and relating to powders for use in dry powder inhalers
GB9703673D0 (en) * 1997-02-21 1997-04-09 Bradford Particle Design Ltd Method and apparatus for the formation of particles
US20070212422A1 (en) * 1999-11-10 2007-09-13 Manfred Keller Dry powder for inhalation
US20060171899A1 (en) * 1998-12-10 2006-08-03 Akwete Adjei Water-stabilized aerosol formulation system and method of making
HUP0200185A3 (en) * 1999-03-05 2006-07-28 Chiesi Farma Spa Improved powdery pharmaceutical compositions for inhalation
IT1309592B1 (it) * 1999-03-05 2002-01-24 Chiesi Farma Spa Particelle veicolo modificate da utilizzarsi nella preparazione diformulazioni farmaceutiche sotto forma di polimeri per inalazione e
GB0009468D0 (en) * 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formulations for use in inhaler devices
GB0009469D0 (en) 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formalities for use in inhaler devices
PE20011227A1 (es) * 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0012260D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
GB0012261D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel process
DK1913939T3 (en) * 2000-06-27 2017-09-18 Vectura Ltd Formulations for use in inhalers
GB0027357D0 (en) * 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
JP4380988B2 (ja) † 2000-11-30 2009-12-09 ヴェクトゥラ リミテッド 医薬組成物に用いられる粒子の製造方法
DE60140268D1 (de) * 2000-11-30 2009-12-03 Vectura Ltd Partikel zur verwendung in einer pharmazeutischen zusammensetzung
PT1920763E (pt) 2000-11-30 2014-06-25 Vectura Ltd Composições farmacêuticas para inalação
WO2002056948A1 (en) 2001-01-17 2002-07-25 Vectura Limited An inhaler device
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
AU2002333644A1 (en) 2001-09-17 2003-04-01 Glaxo Group Limited Dry powder medicament formulations
US7931533B2 (en) 2001-09-28 2011-04-26 Igt Game development architecture that decouples the game logic from the graphics logics
SE0200312D0 (sv) 2002-02-01 2002-02-01 Astrazeneca Ab Novel composition
EP1498116A1 (en) * 2002-03-20 2005-01-19 Hosokawa Micron Corporation Method of manufacturing chemical-containing composite particles
FI116657B (fi) * 2002-03-28 2006-01-31 Focus Inhalation Oy Menetelmä kantoainehiukkasten käsittelemiseksi ja niiden käyttö
US20030235538A1 (en) * 2002-04-09 2003-12-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Method for the administration of an anticholinergic by inhalation
US7582284B2 (en) * 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
GB0216562D0 (en) 2002-04-25 2002-08-28 Bradford Particle Design Ltd Particulate materials
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
MXPA05001903A (es) * 2002-08-21 2005-04-28 Norton Healthcare Ltd Composicion para inhalacion.
AU2003263717A1 (en) * 2002-09-25 2004-04-19 Astrazeneca Ab A COMBINATION OF A LONG-ACTING Beta2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1452179A1 (en) * 2003-02-27 2004-09-01 CHIESI FARMACEUTICI S.p.A. Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid
EP1617820B1 (en) * 2003-04-14 2018-03-21 Vectura Limited Dry power inhaler devices and dry power formulations for enhancing dosing efficiency
US20060147389A1 (en) * 2004-04-14 2006-07-06 Vectura Ltd. Devices and pharmaceutical compositions for enhancing dosing efficiency
US7094545B2 (en) 2003-04-30 2006-08-22 Ferring Bv Pharmaceutical composition as solid dosage form and method for manufacturing thereof
EP1643973A1 (en) * 2003-07-11 2006-04-12 Glaxo Group Limited Pharmaceutical formulations comprising magnesium stearate
JP2009514779A (ja) * 2003-07-11 2009-04-09 グラクソ グループ リミテッド 医薬製剤
CN1826099B (zh) * 2003-07-25 2010-06-09 凡林有限公司 固体剂型药物组合物及其制造方法
SI1500390T1 (sl) 2003-07-25 2006-02-28 Ferring Bv Farmacevtski dezmopresinski sestavek kot trdna dozirna oblika in postopek za njegovo pripravo
US20060292081A1 (en) * 2003-09-15 2006-12-28 Vectura Limited Methods for preparing pharmaceutical compositions
GB0321607D0 (en) * 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
GB0324918D0 (en) * 2003-10-24 2003-11-26 Glaxo Group Ltd Composition
GB0326632D0 (en) 2003-11-14 2003-12-17 Jagotec Ag Dry powder formulations
SE0303570L (sv) * 2003-12-03 2005-06-04 Microdrug Ag Fukt-känslig medicinsk produkt
SE0303571D0 (sv) * 2003-12-03 2003-12-22 Microdrug Ag Medical product for moisture-sensitive medicaments
SE0303269L (sv) * 2003-12-03 2005-06-04 Microdrug Ag Medicinsk produkt
WO2005053647A1 (en) * 2003-12-03 2005-06-16 Microdrug Ag Medical product containing tiotropium
SE0303569L (sv) * 2003-12-03 2005-06-04 Microdrug Ag DPI för avlämning av fuktkänsliga medikament
SE0303270L (sv) * 2003-12-03 2005-06-04 Microdrug Ag Metod för administration av tiotropium
US7018653B2 (en) 2003-12-29 2006-03-28 Ferring B.V. Method for preparing solid dosage form of desmopressin
JO3102B1 (ar) * 2004-03-17 2017-09-20 Chiesi Framaceutici S P A صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة
PT3520779T (pt) 2004-04-23 2022-03-22 Cydex Pharmaceuticals Inc Formulação de dpi contendo éter sulfoalquílicociclodextrina
GB0409703D0 (en) 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
GB0425758D0 (en) * 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
GB0426301D0 (en) * 2004-11-30 2004-12-29 Vectura Ltd Pharmaceutical formulations
ES2613391T3 (es) 2005-02-10 2017-05-24 Glaxo Group Limited Procedimientos de fabricación de lactosa que utilizan técnicas de preclasificación y formulaciones farmacéuticas formadas a partir de la misma
BRPI0608844A2 (pt) * 2005-03-09 2010-02-02 Ono Pharmaceutical Co partìcula e preparação que contém a partìcula
MX2007012084A (es) * 2005-03-30 2007-11-21 Schering Corp Medicamentos y metodos que combinan un anticolinergico, un corticosteroide y un agonista beta de accion prolongada.
TWI274641B (en) * 2005-08-30 2007-03-01 Rexon Ind Corp Ltd Cutting machine
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
GB0525254D0 (en) 2005-12-12 2006-01-18 Jagotec Ag Powder compositions for inhalation
GB0613161D0 (en) 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
GB0622818D0 (en) * 2006-11-15 2006-12-27 Jagotec Ag Improvements in or relating to organic compounds
EP1944018A1 (en) * 2007-01-10 2008-07-16 CHIESI FARMACEUTICI S.p.A. Micronised particles of low-dosage strength active agents for powder formulations for inhalation
ES2538082T3 (es) 2007-02-11 2015-06-17 Map Pharmaceuticals Inc Método de administración terapéutica de DHE para permitir el rápido alivio de migraña mientras que se minimiza el perfil de efectos secundarios
CN101861311A (zh) 2007-07-21 2010-10-13 阿尔巴尼分子研究公司 5-吡啶酮取代的吲唑
CA2722611A1 (en) 2007-11-21 2009-05-28 Decode Genetics Ehf Biaryl pde4 inhibitors for treating pulmonary and cardiovascular disorders
CA2727055C (en) 2008-01-11 2016-12-20 Albany Molecular Research, Inc. (1-azinone) -substituted pyridoindoles as mch antagonists
US8426673B2 (en) 2008-01-11 2013-04-23 Astellas Pharma, Inc. Pathological animal model for pelvic pain syndrome
EP2080508A1 (en) 2008-01-15 2009-07-22 CHIESI FARMACEUTICI S.p.A. Dry powder formulation comprising an anticholinergic drug
WO2010059836A1 (en) 2008-11-20 2010-05-27 Decode Genetics Ehf Substituted aza-bridged bicyclics for cardiovascular and cns disease
EP2191821A1 (en) * 2008-11-26 2010-06-02 CHIESI FARMACEUTICI S.p.A. Microparticles comprising a salt of 8-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone having improved adhesion properties for dry powder inhalation
CN102361876B (zh) 2009-01-26 2015-02-04 以色列生物研究所 二环杂环螺环化合物
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
WO2010097188A1 (en) * 2009-02-25 2010-09-02 Chiesi Farmaceutici S.P.A. Inhalation particles comprising a salt of carmoterol and a corticosteroid
US11116721B2 (en) 2009-02-26 2021-09-14 Glaxo Group Limited Pharmaceutical formulations comprising 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl) phenol
EP2421514A2 (en) * 2009-04-24 2012-02-29 Schering Corporation Agglomerate formulations useful in dry powder inhalers
WO2011015289A1 (en) 2009-08-04 2011-02-10 Chiesi Farmaceutici S.P.A. 8-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl] amino]ethyl]-2(1h)-quinolinone hemi-fumarate
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
EP2360147A1 (en) 2010-02-22 2011-08-24 CHIESI FARMACEUTICI S.p.A. Process for preparing crystalline particles of a salt of 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino] ethyl]-2(1H)-quinolinone (carmoterol)
AU2011234751B2 (en) 2010-04-01 2016-03-17 Chiesi Farmaceutici S.P.A. Process for preparing carrier particles for dry powders for inhalation
RU2580312C2 (ru) * 2010-04-21 2016-04-10 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Способ получения частиц с пониженным электростатическим зарядом
PT2563813E (pt) 2010-04-30 2015-11-26 Alexion Pharma Inc Anticorpos anti-c5a e métodos para utilização dos anticorpos
EP2575786B1 (en) 2010-06-03 2017-11-15 Sima Patent ve Lisanslama Hizmetleri Ltd.Sti. Process for dry powder formulations
EP2585047A1 (en) * 2010-06-22 2013-05-01 Chiesi Farmaceutici S.p.A. Dry powder formulation comprising an antimuscarinic drug
MX346424B (es) 2010-08-03 2017-03-21 Chiesi Farm Spa Formulacion de polvo seco que comprende un inhibidor de fosfodiesterasa.
WO2012028745A1 (en) * 2010-09-03 2012-03-08 Pharmaterials Limited Pharmaceutical composition suitable for use in a dry powder inhaler
RU2017144619A (ru) 2010-09-29 2019-02-20 Пулмэтрикс, Инк. Катионы одновалентных металлов сухих порошков для ингаляций
EP2621494B1 (en) 2010-09-30 2018-11-07 Chiesi Farmaceutici S.p.A. Use of magnesium stearate in dry powder formulations for inhalation
UY33337A (es) 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
US9808030B2 (en) 2011-02-11 2017-11-07 Grain Processing Corporation Salt composition
TR201205852A2 (tr) * 2011-06-02 2012-12-21 Bi̇lgi̇ç Mahmut Geliştirilmiş yeni kuru toz formülasyonu.
TR201105367A2 (tr) * 2011-06-02 2012-12-21 Bi̇lgi̇ç Mahmut Akış özellikleri geliştirilmiş bir kuru toz formülasyonu.
WO2013109210A1 (en) * 2012-01-16 2013-07-25 Mahmut Bilgic Dry powder formulations comprising budesonide
WO2013109215A1 (en) * 2012-01-16 2013-07-25 Mahmut Bilgic Preparation of dry powder formulations comprising formoterol
WO2013109211A1 (en) * 2012-01-16 2013-07-25 Mahmut Bilgic Dry powder formulations comprising r-formoterol as active agent
EP3527197B1 (en) 2012-01-25 2022-09-07 Chiesi Farmaceutici S.p.A. Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation
US20150010527A1 (en) 2012-02-01 2015-01-08 Protalix Ltd. Dnase i polypeptides, polynucleotides encoding same, methods of producing dnase i and uses thereof in therapy
US20150136130A1 (en) 2012-02-29 2015-05-21 Pulmatrix, Inc. Inhalable dry powders
US20150174158A1 (en) 2012-03-07 2015-06-25 Advanced Inhalation Therapies (Ait) Ltd. Inhalation of nitric oxide for treating respiratory diseases
TWI617561B (zh) 2012-03-13 2018-03-11 瑞斯比維特有限公司 呈晶體型式之新穎化合物，包含其之醫藥組成物，製備該化合物之方法及包括該組成物之吸入裝置
RU2666963C2 (ru) 2012-04-13 2018-09-13 Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Агрегированные частицы
WO2014007771A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising muscarinic receptor antagonist
US10111957B2 (en) * 2012-07-05 2018-10-30 Arven Ilac Snayi ve Ticaret A.S. Inhalation compositions comprising glucose anhydrous
CN109846862A (zh) 2012-10-25 2019-06-07 通用医疗公司 治疗阿尔茨海默病及相关疾病的组合疗法
US11052202B2 (en) 2012-11-07 2021-07-06 Chiesi Farmaceutici S.P.A. Drug delivery device for the treatment of patients with respiratory diseases
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
DK2948148T3 (da) 2013-01-28 2020-10-26 Incozen Therapeutics Pvt Ltd Metoder til behandling af autoimmune, åndedræts- og betændelsesforstyrrelser ved inhalation af roflumilast n-oxid
GB201305825D0 (en) 2013-03-28 2013-05-15 Vectura Ltd New use
JP6505079B2 (ja) 2013-03-29 2019-04-24 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体ｃ５を標的とする治療薬の血清半減期を増加させるための組成物及び方法
WO2014178891A1 (en) 2013-04-30 2014-11-06 Otitopic Inc. Dry powder formulations and methods of use
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
PT2821061T (pt) * 2013-07-01 2018-03-13 Arven Ilac Sanayi Ve Ticaret As Novas formulações para inalação
EP3019153B1 (en) * 2013-07-11 2018-09-05 Chiesi Farmaceutici S.p.A. Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic for administration by inhalation
US20160235667A1 (en) * 2013-10-02 2016-08-18 Vectura Limited Method and apparatus for making compositions for pulmonary administration
US9427376B2 (en) * 2013-10-10 2016-08-30 Chiesi Farmaceutici S.P.A. Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient
EP3060205A4 (en) 2013-10-22 2017-06-28 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
NZ711451A (en) 2014-03-07 2016-05-27 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
US9554992B2 (en) 2014-06-09 2017-01-31 Chiesi Farmaceutici S.P.A. Inhalation particles comprising a combination of an anticholinergic, a corticosteroid and a beta-adrenergic
TR201407010A2 (tr) 2014-06-16 2015-12-21 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Vilanterol formülasyonları.
EP2957552B1 (en) 2014-06-16 2020-01-22 Arven Ilac Sanayi Ve Ticaret A.S. Vilanterol formulations
WO2016005443A1 (en) * 2014-07-09 2016-01-14 Arven Ilac Sanayi Ve Ticaret A.S. A process for the preparation of formulations for inhalation
WO2016057693A1 (en) 2014-10-10 2016-04-14 Alnylam Pharmaceuticals, Inc. Methods and compositions for inhalation delivery of conjugated oligonucleotide
CN107106641B (zh) 2014-10-31 2021-12-21 葛兰素史密斯克莱知识产权发展有限公司 粉末制剂
RU2693201C1 (ru) * 2015-06-23 2019-07-01 Шлюмберже Текнолоджи Б.В. Распознание расклинивающего агента с помощью мобильного устройства
US11224594B2 (en) * 2015-09-16 2022-01-18 Philip Morris Products S.A. Nicotine formulations and methods of making and using the same
PT3628331T (pt) * 2015-11-16 2021-10-20 Chiesi Farm Spa Processo para preparar uma formulação de pó seco que compreende um anticolinérgico, um corticosteroide e um beta-adrenérgico
DK3689379T3 (da) * 2015-11-16 2021-09-06 Chiesi Farm Spa Fremgangsmåde til fremstilling af en tørpulverformulering omfattende et anticholinergikum, et corticosteroid og et beta-adrenergikum
AU2016376033A1 (en) * 2015-12-24 2018-06-28 Philip Morris Products S.A. Nicotine particle capsule
US20170342139A1 (en) 2016-05-27 2017-11-30 Alexion Pharmaceuticals, Inc. Methods for Treatment of Refractory Generalized Myasthenia Gravis
EP3506894B1 (en) 2016-08-31 2023-08-23 The General Hospital Corporation Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
CA3060020A1 (en) * 2017-05-11 2018-11-15 Chiesi Farmaceutici S.P.A. A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
CA3059824A1 (en) 2017-05-11 2018-11-15 Chiesi Farmaceutici S.P.A. A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
US10583085B2 (en) 2017-05-17 2020-03-10 Chiesi Farmaceutici S.P.A. Carrier particles for dry powder formulations for inhalation
KR20200027971A (ko) 2017-07-14 2020-03-13 싸이톰스 테라퓨틱스, 인크. 항-cd166 항체 및 이의 용도
CN111107788B (zh) * 2017-07-26 2023-12-19 深圳帧观德芯科技有限公司 具有空间扩展性x射线源的x射线成像系统
US11365241B2 (en) 2017-07-27 2022-06-21 Alexion Pharmaceuticals, Inc. High concentration anti-C5 antibody formulations
WO2019060604A1 (en) 2017-09-20 2019-03-28 Teva Branded Pharmaceutical Products R&D, Inc. INHALABLE MEDICINE
WO2019060797A1 (en) 2017-09-22 2019-03-28 Teva Branded Pharmaceutical Products R&D, Inc. PROCESS FOR PRODUCING POWDERS FOR INHALING
CN115919780A (zh) * 2017-09-22 2023-04-07 维克图拉公司 含有硬脂酸镁的干粉组合物
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
WO2019067708A1 (en) * 2017-09-27 2019-04-04 Teva Branded Pharmaceutical Products R&D, Inc. METHOD FOR DECREASING PARTICLE SIZE
AU2018354404B2 (en) 2017-10-26 2025-10-30 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-C5 antibodies for treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) and Atypical Hemolytic Uremic Syndrome (aHUS)
JP7520725B2 (ja) 2018-05-31 2024-07-23 アレクシオン ファーマシューティカルズ， インコーポレイテッド 小児患者における発作性夜間ヘモグロビン尿症（ｐｎｈ）の治療のための抗ｃ５抗体の用量および投与
US12460012B2 (en) 2018-06-04 2025-11-04 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-C5 antibodies for treatment of atypical hemolytic uremic syndrome (aHUS) in pediatric patients
EP3814373A1 (en) 2018-06-28 2021-05-05 Alexion Pharmaceuticals, Inc. Methods of producing anti-c5 antibodies
CA3105392A1 (en) * 2018-07-02 2020-01-09 The General Hospital Corporation Powdered formulations of cromolyn sodium and .alpha.-lactose
AU2019311268B2 (en) 2018-07-27 2025-01-16 Chiesi Farmaceutici S.P.A. Novel carrier particles for dry powder formulations for inhalation
JP2021536467A (ja) 2018-09-06 2021-12-27 インノファーマスクリーン インコーポレイテッド 喘息またはパーキンソン病の処置のための方法および組成物
EP3873574B1 (en) 2018-10-30 2023-12-06 Chiesi Farmaceutici S.p.A. Apparatus to administer drugs to mechanically ventilated patients
WO2020092549A1 (en) 2018-10-30 2020-05-07 Alexion Pharmaceuticals, Inc. Subcutaneous dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh)
KR20210113610A (ko) 2018-12-10 2021-09-16 더 제너럴 하스피탈 코포레이션 크로몰린 에스테르 및 이의 용도
IL283734B2 (en) 2018-12-12 2025-03-01 Kite Pharma Inc Chimeric antigen receptors and CAR-T cells and methods of use
CA3138530A1 (en) 2019-04-29 2020-11-05 Insmed Incorporated Dry powder compositions of treprostinil prodrugs and methods of use thereof
AU2020356243A1 (en) 2019-09-24 2022-03-24 Chiesi Farmaceutici S.P.A. Novel carrier particles for dry powder formulations for inhalation
IL297023A (en) 2020-04-06 2022-12-01 Massachusetts Gen Hospital Methods for treating inflammatory conditions caused by the corona virus
CA3176425A1 (en) 2020-04-24 2021-10-28 Millennium Pharmaceuticals, Inc. Anti-cd19 antibodies and uses thereof
WO2021237109A1 (en) 2020-05-22 2021-11-25 Trailhead Biosystems Inc. Combination therapy for treatment of viral infections
CN112451509B (zh) * 2020-12-19 2023-03-07 沈阳药科大学 一种川丁特罗吸入粉雾剂及其制备方法
EP4320149A1 (en) 2021-04-09 2024-02-14 Takeda Pharmaceutical Company Limited Antibodies targeting complement factor d and uses therof
WO2022232035A1 (en) 2021-04-26 2022-11-03 Millennium Pharmaceuticals, Inc. Anti-adgre2 antibodies and uses thereof
EP4330284A2 (en) 2021-04-26 2024-03-06 Millennium Pharmaceuticals, Inc. Anti-clec12a antibodies and uses thereof
MX2024004365A (es) 2021-10-20 2024-04-25 Takeda Pharmaceuticals Co Composiciones que actuan sobre el antigeno de maduracion de linfocitos b (bcma) y metodos de uso de las mismas.
CN118475343A (zh) 2021-12-21 2024-08-09 凯西制药公司 填充在具有改善的耐湿性的吸入器中的干粉制剂
CN118414147A (zh) 2021-12-21 2024-07-30 凯西制药公司 填充在具有改善的耐湿性的吸入器中的干粉制剂
WO2023150747A1 (en) 2022-02-07 2023-08-10 Insmed Incorporated Dry powder compositions of bedaquiline and salts and methods of use thereof
CA3268243A1 (en) 2022-09-22 2024-03-28 Chiesi Farm Spa CAPSULE INHALATOR FOR THE ADMINISTRATION OF A PHOSPHODIESTERASE-4 INHIBITOR

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1242211A (en) 1967-08-08 1971-08-11 Fisons Pharmaceuticals Ltd Pharmaceutical composition
GB1381872A (en) 1971-06-22 1975-01-29 Fisons Ltd Pharmaceutical compositions for inhalation
GB1520247A (en) 1974-08-10 1978-08-02 Fisons Ltd Pelletised medicament formulations
GB1571629A (en) 1977-11-30 1980-07-16 Fisons Ltd Pharmaceutical compositions containing beclomethasone dipropionate
US4349542A (en) * 1979-06-08 1982-09-14 National Research Development Corporation Mixture containing active ingredient and dendritic crystalline sugar for tableting
IT1204826B (it) 1986-03-04 1989-03-10 Chiesi Farma Spa Composizioni farmaceutiche per inalazione
US5376386A (en) * 1990-01-24 1994-12-27 British Technology Group Limited Aerosol carriers
EP0441740B1 (de) 1990-01-29 1993-09-22 Ciba-Geigy Ag Verfahren und Vorrichtung zur Dosierung eines feinkörnigen Pulvers
DE4140689B4 (de) 1991-12-10 2007-11-22 Boehringer Ingelheim Kg Inhalationspulver und Verfahren zu ihrer Herstellung
AU660824B2 (en) 1992-06-12 1995-07-06 Teijin Limited Pharmaceutical preparation for intra-airway administration
GB2269992A (en) 1992-08-14 1994-03-02 Rh Ne Poulenc Rorer Limited Powder inhalation formulations
GB9322014D0 (en) * 1993-10-26 1993-12-15 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
GB9404945D0 (en) 1994-03-15 1994-04-27 Glaxo Group Ltd Pharmaceutical composition
DE4425255A1 (de) 1994-07-16 1996-01-18 Asta Medica Ag Formulierung zur inhalativen Applikation
SE9700136D0 (sv) 1997-01-20 1997-01-20 Astra Ab New formulation
SE9700134D0 (sv) 1997-01-20 1997-01-20 Astra Ab New formulation
GB9501841D0 (en) * 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
GB9515182D0 (en) 1995-07-24 1995-09-20 Co Ordinated Drug Dev Improvements in and relating to powders for use in dry powder inhalers
US6565885B1 (en) * 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6475462B1 (en) * 1997-09-30 2002-11-05 Mortimer Technology Holdings Limited Process and apparatus for treating particulate matter
NZ506289A (en) * 1998-03-16 2004-12-24 Nektar Therapeutics Aerosolized active agent delivery to the lungs at a flow rate of less than 17 liters per minute
CA2347856C (en) 1998-11-13 2009-02-17 Jago Research Ag Dry powder for inhalation
GB9826783D0 (en) * 1998-12-04 1999-01-27 Scherer Ltd R P Inhalation powders
HUP0200185A3 (en) 1999-03-05 2006-07-28 Chiesi Farma Spa Improved powdery pharmaceutical compositions for inhalation
ES2343124T3 (es) * 1999-10-29 2010-07-23 Novartis Ag Composiciones de polvo seco con dispersabilidad mejorada.
GB0009468D0 (en) * 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formulations for use in inhaler devices
GB0009469D0 (en) * 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formalities for use in inhaler devices
PE20011227A1 (es) * 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
DK1913939T3 (en) * 2000-06-27 2017-09-18 Vectura Ltd Formulations for use in inhalers

Also Published As

Publication number Publication date
DE60125344T2 (de) 2007-07-19
CA2406119A1 (en) 2001-10-25
EP1276473A2 (en) 2003-01-22
GB0109431D0 (en) 2001-06-06
HUP1300117A2 (en) 2003-07-28
ES2275669T3 (es) 2007-06-16
PE20011227A1 (es) 2002-01-07
DE60125344D1 (de) 2007-02-01
AU4859501A (en) 2001-10-30
ATE348603T1 (de) 2007-01-15
HU229270B1 (en) 2013-10-28
ATE513542T1 (de) 2011-07-15
EP1719505A3 (en) 2007-07-18
SI1719505T1 (sl) 2011-12-30
NO336687B1 (no) 2015-10-19
CZ301904B6 (cs) 2010-07-28
DE60131265T2 (de) 2008-03-06
ES2292576T3 (es) 2008-03-16
CA2406201A1 (en) 2001-10-25
HUP0300499A2 (en) 2003-07-28
BR0110301A (pt) 2003-12-30
PL358640A1 (en) 2004-08-09
JP2012255035A (ja) 2012-12-27
EP1829533B1 (en) 2011-06-22
NO332025B1 (no) 2012-05-29
WO2001078693A2 (en) 2001-10-25
NZ521887A (en) 2004-06-25
CY1107315T1 (el) 2012-11-21
WO2001078694A2 (en) 2001-10-25
HUP0300593A2 (hu) 2003-09-29
PL204251B1 (pl) 2009-12-31
DK1274406T3 (da) 2007-01-22
EP1274406A2 (en) 2003-01-15
EP2272508B1 (en) 2020-03-25
ATE377416T1 (de) 2007-11-15
CA2405767C (en) 2011-07-05
SK284248B6 (sk) 2004-12-01
US8182791B2 (en) 2012-05-22
HUP0300490A2 (en) 2003-07-28
EP1276472A2 (en) 2003-01-22
AU784719B2 (en) 2006-06-01
US20030180227A1 (en) 2003-09-25
CN1424909A (zh) 2003-06-18
GB0109432D0 (en) 2001-06-06
JP2003530425A (ja) 2003-10-14
CZ20023437A3 (cs) 2003-02-12
DK1719505T3 (da) 2011-12-05
ES2272473T3 (es) 2007-05-01
HU230464B1 (hu) 2016-07-28
MXPA02010213A (es) 2005-07-01
CA2406119C (en) 2009-07-07
EP1719505A2 (en) 2006-11-08
EP1276472B1 (en) 2006-12-20
EP1274406B1 (en) 2006-09-13
CA2405767A1 (en) 2001-10-25
SI1274406T1 (sl) 2007-02-28
AU4858101A (en) 2001-10-30
DZ3315A1 (fr) 2001-10-25
PT1719505E (pt) 2011-10-24
NO20024980L (no) 2002-12-17
PL204213B1 (pl) 2009-12-31
HUP0300593A3 (en) 2006-07-28
EE200200593A (et) 2004-04-15
WO2001078694A3 (en) 2002-03-14
TNSN01060A1 (fr) 2005-11-10
NO20024980D0 (no) 2002-10-16
NO20024973L (no) 2002-12-16
DE60123031T2 (de) 2007-03-08
EP2272508A2 (en) 2011-01-12
NO20024971D0 (no) 2002-10-16
MY129384A (en) 2007-03-30
NO342999B1 (no) 2018-09-24
IL152306A0 (en) 2003-05-29
MXPA02010212A (es) 2004-06-29
CA2406201C (en) 2011-03-22
MXPA02010218A (es) 2003-05-23
KR20030069047A (ko) 2003-08-25
SK14912002A3 (sk) 2003-03-04
US7223748B2 (en) 2007-05-29
PT1274406E (pt) 2007-01-31
SA01220062B1 (ar) 2006-11-05
EP1829533A2 (en) 2007-09-05
NO20024973D0 (no) 2002-10-16
US20030175214A1 (en) 2003-09-18
PL358875A1 (en) 2004-08-23
EP1276473B1 (en) 2007-11-07
EE05257B1 (et) 2010-02-15
WO2001078695A2 (en) 2001-10-25
ATE521340T1 (de) 2011-09-15
ATE339195T1 (de) 2006-10-15
WO2001078693A3 (en) 2002-01-17
BR0110141A (pt) 2003-01-28
BR0110139A (pt) 2002-12-31
EP1719505B1 (en) 2011-08-24
EP1829533A3 (en) 2007-10-31
US20050201950A1 (en) 2005-09-15
US20120308613A1 (en) 2012-12-06
GB2363987A (en) 2002-01-16
PT1276472E (pt) 2007-02-28
NO20110885L (no) 2002-12-17
DK1276472T3 (da) 2007-04-16
EP2272508A3 (en) 2012-01-18
HU229797B1 (en) 2014-07-28
GB2363988A (en) 2002-01-16
DE60123031D1 (de) 2006-10-26
DE60131265D1 (de) 2007-12-20
MA26892A1 (fr) 2004-12-20
PL359289A1 (en) 2004-08-23
WO2001078695A3 (en) 2002-03-14
AU2001258343A1 (en) 2001-10-30
US6884794B2 (en) 2005-04-26

Similar Documents

Publication Publication Date Title
NO20024971L (no) Forbedringer av formuleringer for anvendelse i inhaleringsinnretninger
EA200400045A1 (ru) Система для ингаляции сухим порошком для транспульмонарного применения
GB2453272A (en) Lumen-traveling device
TR200101442T2 (tr) HFA 227 ve HFA 137 ihtiva eden farmasötik aeorosol bileşimi
NO20012346L (no) Törrpulver for inhalering
MXPA02012023A (es) Administracion altamente eficiente de un aerosol de masa terapeutica grande.
DE60013425D1 (de) Arzneizusammensetzungen zur aerosolbildung und zu inhalationszwecken
ATE494030T1 (de) Pulverinhalator
MY127145A (en) Stable pharmaceutical solution formulations for pressurised metered dose inhalers
GEP20064002B (en) Metered dose inhaler
DE69936268D1 (de) Verbesserte pulverformulierungen zur inhalation
DE60036534D1 (de) Feste pharmazeutische formulierungen auf basis von sulfoalkylethern des cyclodextrins zur verzögerten freisetzung
TR199700722T1 (xx) Kuru toz p�sk�rt�c�lerde kullan�lmak i�in ta��y�c� par�ac�klar
EA199900201A1 (ru) Фармацевтическая аэрозольная композиция
DK1658047T3 (da) Spraytörret amorft pulver med en lav resterende fugtighed og udmærket lagerstabilitet
ATE219932T1 (de) Neue feste dosisform enthaltend nanopartikelnaproxen
CY1110136T1 (el) Συνθεσεις ξηρης σκονης με βελτιωμενη διασπαρσιμοτητα
CO5280133A1 (es) Dispositivo y sistema para aerosolizar formulaciones farmaceuticas
DE60113079D1 (de) Inhalationsapparat
ATE286057T1 (de) Pharmazeutische zubereitungen enthaltend clavulansäure
PL318789A1 (en) Sprayable film-forming system capable to release an active substance contained in them and intended to use them on plants
EP2328556A4 (en) FORMULATIONS WITH LARGE SUPPORT PARTS FOR AEROSOLS FOR THE INHALATION OF DRY POWDER
DK1019033T3 (da) Ny formulering til inhalation der har en hældt bulkdensitet på fra 0,28 til 0,38 g/ml, som omfatter budesonid
BRPI0508549A (pt) inalador de pó seco de dose unica
SE0003082D0 (sv) Metered electro-dose

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application